Losartan
MPS VI
Hospital de Clinicas de Porto AlegreSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the MPS VI cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
IDURONIDASE, .ALPHA.-L-(8-HISTIDINE) (HUMAN) University of California, San Francisco | Phase 1 | CC |
Same molecule, other indications
Losartan is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →